South Africa’s rollout of the twice-yearly HIV prevention injection lenacapavir could transform the fight against HIV, but ...

Share on Pinterest A drug used to treat HIV infections can also effectively prevent them, a new clinical trial demonstrates. Image credit: luza studios/Getty Images. Human immunodeficiency virus (HIV) ...

Lenacapavir is a gamechanger in the field of global health, signifying a shift from HIV prevention that requires a daily ...

As South Africa becomes the ninth African country to introduce the use of new long-acting drug lenacapavir for HIV prevention ...

The Gauteng health department has begun a phased rollout of Lenacapavir, a twice-yearly HIV prevention injection now available at selected public health facilities across the province. This comes as ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

The rollout forms part of a nationwide initiative led and announced by President Cyril Ramaphosa to expand HIV prevention.

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted. If ...

Premier Kagiso Lazarus Mokgosi and Health MEC Sello Lehari led the launch, which saw the province administer its first ...

(RTTNews) - According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent reduced risk of HIV infection overall. The Phase III ...

History was made in the Mpumalanga province of South Africa on Friday, 5 June, as 21-year-old Jane Mndebele became the first ...

Tuesday, Gilead Sciences Inc (NASDAQ:GILD) reported fourth-quarter 2024 adjusted EPS of $1.90, beating the consensus of $1.70. Sales increased 6% year over year to $7.57 billion, beating the consensus ...